BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31288852)

  • 1. An unusual recurrent high-grade glioneuronal tumor with MAP2K1 mutation and CDKN2A/B homozygous deletion.
    Cheaney B; Bowden S; Krause K; Sloan EA; Perry A; Solomon DA; Han SJ; Wood MD
    Acta Neuropathol Commun; 2019 Jul; 7(1):110. PubMed ID: 31288852
    [No Abstract]   [Full Text] [Related]  

  • 2. CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors.
    Xerri L; Adélaïde J; Popovici C; Garnier S; Guille A; Mescam-Mancini L; Laurent C; Brousset P; Coze C; Michel G; Chaffanet M; Bouabdallah R; Coso D; Bertucci F; Birnbaum D
    Am J Surg Pathol; 2018 Feb; 42(2):150-159. PubMed ID: 29194093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic landscape of ganglioglioma.
    Pekmezci M; Villanueva-Meyer JE; Goode B; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Chamyan G; Maher OM; Khatib Z; Kleinschmidt-DeMasters BK; Samuel D; Mueller S; Banerjee A; Clarke JL; Cooney T; Torkildson J; Gupta N; Theodosopoulos P; Chang EF; Berger M; Bollen AW; Perry A; Tihan T; Solomon DA
    Acta Neuropathol Commun; 2018 Jun; 6(1):47. PubMed ID: 29880043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas.
    Marker DF; Pearce TM
    Acta Neuropathol Commun; 2020 Oct; 8(1):169. PubMed ID: 33081848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma.
    Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B
    J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
    Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
    J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDKN2A/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
    Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
    J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
    Saxena A; Robertson JT; Ali IU
    Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neurogenic tumor containing a low-grade malignant peripheral nerve sheath tumor (MPNST) component with loss of p16 expression and homozygous deletion of CDKN2A/p16: a case report showing progression from a neurofibroma to a high-grade MPNST.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(5):5113-20. PubMed ID: 26191206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
    Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
    Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of p16
    Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
    J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    Vizcaino MA; Giannini C; Lalich D; Nael A; Jenkins RB; Tran Q; Orr BA; Abdullaev Z; Aldape K; Vaubel RA
    J Neuropathol Exp Neurol; 2024 May; 83(6):416-424. PubMed ID: 38699943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
    Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
    Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homozygous deletion of CDKN2A (p16, p14) and CDKN2B (p15) genes is a poor prognostic factor in adult but not in childhood B-lineage acute lymphoblastic leukemia: a comparative deletion and hypermethylation study.
    Kim M; Yim SH; Cho NS; Kang SH; Ko DH; Oh B; Kim TY; Min HJ; She CJ; Kang HJ; Shin HY; Ahn HS; Yoon SS; Kim BK; Shin HR; Han KS; Cho HI; Lee DS
    Cancer Genet Cytogenet; 2009 Nov; 195(1):59-65. PubMed ID: 19837270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
    Sonoda Y; Yoshimoto T; Sekiya T
    Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.
    Dyke J; Calapre L; Beasley A; Gray E; Allcock R; Bentel J
    Pathol Res Pract; 2022 Jan; 229():153724. PubMed ID: 34942511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion.
    Chonabayashi K; Tamori S; Taniwaki M; Fujita H; Shimazu Y; Matsui Y; Hishizawa M; Usami K; Takaori-Kondo A
    Ann Hematol; 2014 May; 93(5):893-4. PubMed ID: 23989669
    [No Abstract]   [Full Text] [Related]  

  • 20. [Homozygous deletion of p16 and p15 genes in laryngeal squamous cell carcinoma].
    Li F; Kang N; Li Y; He G; Lin C; Sun X; Gao H; Sun K
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):30-2. PubMed ID: 11836682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.